Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II/III, Multicentre, 8-week Run-in Phase Followed by a 12-week, Prospective, Parallel-group, Double-blind, Randomized Withdrawal, Placebo-controlled Study, with a 52 Week Open Label Extension, to Evaluate the Efficacy and Safety of Daily 1.5 to 3.5 Mg Basimglurant in Patients with Pain Associated with Trigeminal Neuralgia with Suboptimal Response to Their Current Anti-pain Therapy.

Next Previous
Trial Profile

A Phase II/III, Multicentre, 8-week Run-in Phase Followed by a 12-week, Prospective, Parallel-group, Double-blind, Randomized Withdrawal, Placebo-controlled Study, with a 52 Week Open Label Extension, to Evaluate the Efficacy and Safety of Daily 1.5 to 3.5 Mg Basimglurant in Patients with Pain Associated with Trigeminal Neuralgia with Suboptimal Response to Their Current Anti-pain Therapy.

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 13 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Basimglurant (Primary)
  • Indications Facial pain; Pain; Trigeminal neuralgia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms LibraTN
  • Sponsors Noema Pharma

Most Recent Events

  • 13 Jan 2026 Planned End Date changed from 1 Feb 2027 to 24 Apr 2027.
  • 13 Jan 2026 Planned primary completion date changed from 31 Dec 2025 to 2 Feb 2027.
  • 11 Jul 2025 Planned primary completion date changed from 31 Oct 2025 to 31 Dec 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top